Severe SARS-CoV-2 patients develop a higher specific T-cell response.
ELISpot
SARS‐CoV‐2
T cells
Journal
Clinical & translational immunology
ISSN: 2050-0068
Titre abrégé: Clin Transl Immunology
Pays: Australia
ID NLM: 101638268
Informations de publication
Date de publication:
2020
2020
Historique:
received:
18
08
2020
revised:
04
10
2020
revised:
01
11
2020
accepted:
01
11
2020
entrez:
30
12
2020
pubmed:
31
12
2020
medline:
31
12
2020
Statut:
epublish
Résumé
Assessment of the adaptive immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is crucial for studying long-term immunity and vaccine strategies. We quantified IFNγ-secreting T cells reactive against the main viral SARS-CoV-2 antigens using a standardised enzyme-linked immunospot assay (ELISpot). Overlapping peptide pools built from the sequences of M, N and S viral proteins and a mix (MNS) were used as antigens. Using IFNγ T-CoV-Spot assay, we assessed T-cell and antibody responses in mild, moderate and severe SARS-CoV-2 patients and in control samples collected before the outbreak. Specific T cells were assessed in 60 consecutive patients (mild, IFNγ T-CoV-Spot assay is a reliable method to explore specific T cells in large cohorts of patients. This test may become a useful tool to assess the long-lived memory T-cell response after vaccination. Our study demonstrates that SARS-CoV-2 patients developing a severe disease achieve a higher adaptive immune response.
Identifiants
pubmed: 33376594
doi: 10.1002/cti2.1217
pii: CTI21217
pmc: PMC7757425
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e1217Informations de copyright
© 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
J Infect Dis. 2020 May 11;221(11):1762-1769
pubmed: 32227123
Vaccine. 2016 Apr 12;34(17):2008-14
pubmed: 26954467
Clin Infect Dis. 2020 May 28;:
pubmed: 32463076
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
Ann Intern Med. 2020 Sep 1;173(5):350-361
pubmed: 32422076
Lancet Infect Dis. 2020 Jun;20(6):656-657
pubmed: 32199493
J Med Virol. 2020 Sep;92(9):1684-1689
pubmed: 32343415
Clin Infect Dis. 2020 Nov 19;71(16):2150-2157
pubmed: 32442287
J Exp Med. 2005 Nov 7;202(9):1289-300
pubmed: 16275766
J Immunol. 2008 Oct 15;181(8):5490-500
pubmed: 18832706
Science. 2020 Oct 2;370(6512):89-94
pubmed: 32753554
Front Immunol. 2020 May 01;11:827
pubmed: 32425950
JAMA. 2020 Jun 9;323(22):2249-2251
pubmed: 32374370
Emerg Microbes Infect. 2020 Dec;9(1):833-836
pubmed: 32306864
Nat Commun. 2020 Jul 8;11(1):3410
pubmed: 32641700
J Clin Invest. 2020 May 1;130(5):2202-2205
pubmed: 32217834
Nature. 2020 Nov;587(7833):270-274
pubmed: 32726801
Methods Mol Biol. 2012;792:3-23
pubmed: 21956497
Cell Host Microbe. 2020 Apr 8;27(4):671-680.e2
pubmed: 32183941
Cell. 2020 May 28;181(5):1036-1045.e9
pubmed: 32416070
EBioMedicine. 2020 May;55:102763
pubmed: 32361250
Clin Infect Dis. 2020 Nov 19;71(16):2066-2072
pubmed: 32357209
Intensive Care Med. 2020 Jun;46(6):1124-1126
pubmed: 32328726
Cell Mol Immunol. 2020 May;17(5):541-543
pubmed: 32203186
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Nat Rev Immunol. 2012 Feb 17;12(3):180-90
pubmed: 22343569
J Infect Dis. 2020 Aug 17;222(6):910-918
pubmed: 32614392
Cytokine Growth Factor Rev. 2020 Aug;54:62-75
pubmed: 32513566
Circulation. 2020 Jul 14;142(2):184-186
pubmed: 32330083
Science. 2020 Aug 7;369(6504):718-724
pubmed: 32661059
Front Pharmacol. 2017 Jun 08;8:335
pubmed: 28642703
Immunity. 2020 Apr 14;52(4):583-589
pubmed: 32259480